Dimitrios Lamprou (Ph.D., MBA) is Full Professor (Chair) of Biofabrication and Advanced Manufacturing, and Director at MSc Industrial Pharmaceutics at Queen’s University Belfast (QUB). He is also the Chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the Chair of the Academy of Pharmaceutical Sciences (APS) Emerging Technologies Focus Group. Dimitrios, is the author of over 150 peer-reviewed publications, has over 400 conference abstracts, has given over 150 Invited Talks in institutions and conferences across the world, and has secure Funding more than £4M. Dimitrios has been recognised as world leader in 3D Printing & Microfluidics. PubMed-based algorithms placed him in the top 0.088% of scholars in the world writing about 3D Printing and on the top 0.071% of scholars in the world writing about microfluidics, in the past 10-years. Moreover, PubMed-based algorithms placed him in the top 0.63% of scholars in the world writing about nanofibers. Dimitrios has also been named in the Stanford University’s list 2021 & 2022 of World’s Top 2% Scientists, for his research in Pharmaceutics and Biomedical Engineering. His research and academic leadership have been recognized in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award. For more info, please visit www.emergingtechnologieslab.com.
Dimitrios Lamprou (Ph.D., MBA) is Full Professor (Chair) of Biofabrication and Advanced Manufacturing, and Director at MSc Industrial Pharmaceutics at Queen’s University Belfast (QUB). He is also the Chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the Chair of the Academy of Pharmaceutical Sciences (APS) Emerging Technologies Focus Group. Dimitrios, is the author of over 150 peer-reviewed publications, has over 400 conference abstracts, has given over 150 Invited Talks in institutions and conferences across the world, and has secure Funding more than £4M. Dimitrios has been recognised as world leader in 3D Printing & Microfluidics. PubMed-based algorithms placed him in the top 0.088% of scholars in the world writing about 3D Printing and on the top 0.071% of scholars in the world writing about microfluidics, in the past 10-years. Moreover, PubMed-based algorithms placed him in the top 0.63% of scholars in the world writing about nanofibers. Dimitrios has also been named in the Stanford University’s list 2021 & 2022 of World’s Top 2% Scientists, for his research in Pharmaceutics and Biomedical Engineering. His research and academic leadership have been recognized in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award. For more info, please visit www.emergingtechnologieslab.com.
Dr John Maher is the scientific founder and chief scientific officer of Leucid Bio. He is also a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.
Principal Investigator at National Institute for Cellular Biotechnology and an Assistant Professor in the School of Biotechnology, Dublin City University.
Research interests are in the area of Biopharmaceutical Research of CHO cells where she uses proteomic characterisation of recombinant mammalian cells (Chinese hamster ovary (CHO) cells) in order to gain insights to improving productivity of biopharmaceuticals. This involves the analysis of CHO cells under varying bioprocess relevant conditions in order to identify targets that will be used to genetically engineer CHO cells to produce recombinant product (e.g. monoclonal antibodies) more efficiently. She also has particular expertise in the analysis of cellular post-translational modifications (e.g. phosphorylation, ubiquitination, etc.) that play important roles in bioprocess-relevant phenotypes such as growth and productivity
Co-author of over 100 peer-reviewed publications, has edited one book, and co-authored 13 book chapters to date in research areas related to proteomics, bioprocessing and cancer.
Ioanna Tzani received her doctorate degree from University College Cork in 2017, where she studied protein synthesis regulation in cancer and identified previously uncharacterised proteoforms in the commonly mutated tumour suppressor PTEN. Since 2017 she is a member of Dr Colin Clarke’s Systems Biology group in the National Institute for Bioprocessing Research and Training (NIBRT, Dublin). In her current role she studies the effect of cell culture conditions on gene expression and protein synthesis through the application of both bulk and single cell -omics methods, aiming towards improving bioprocessing efficiency and quality and safety of recombinant therapeutic proteins. Her research interests include the application of molecular biology and -omics methods towards improving the production efficiency of advanced therapy medicinal products
Pedro Silva Couto is a post-doctoral research fellow at University College London (UCL). His role is part of a European consortium focused on CAR-T cell manufacturing named Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital (AIDPATH). Pedro previously completed his PhD under the supervision of Dr. Qasim Rafiq at UCL. His work focused on the manufacturing of ex vivo gene therapy and extracellular vesicles using human mesenchymal stromal cells (hMSCs) for clinical applications. Pedro received a Master’s in Biochemical Engineering from IST, Portugal.
Andrew is a Senior CMC Development Director within Evox Therapeutics responsible for the Vector Development and Supply, Cell Line Development and Analytical Development functions. Andrew joined Evox Therapeutics in 2020 to progress the development of exosome drug products. Here he continues his passion for developing novel therapeutics and solving the associated challenges. Prior to Evox, Andrew spent 9 years at Ipsen Bioinnovation working on R&D of novel recombinant botulinum neurotoxins in a variety of different roles encompassing analytical, formulation and process development. Andrew was a significant contributor to publications on the practices and pitfalls of the historical potency measurements of traditional botulinum toxin products and need for standardisation. Andrew began his industry career within cGMP Analytical Development and QC testing of biotherapeutics at Patheon and Covance. Andrew holds a PhD in Structural Biology and an MChem from the University of Sheffield.
JOSEPH M. ROIG obtained his BSc in Science of Chemistry in 1980 (University of Barcelona) and started his professional career at Coulter-Beckman, working in blood cell counting and flow cytometry. He joined COBE BCT (Terumo BCT) in 1991 to help the company start operations in Spain, moving to the US to continue working for them in 2000. During the years that he worked for COBE/Terumo BCT he was involved with all existing apheresis variants (donor collections, leukapheresis, therapeutic apheresis). He joined the Terumo BCT Scientific Support group in 2012 and the Medical Affairs group in 2016, the same year he got a Masters in Transfusion Medicine and Advanced Cell Therapies (EMTACT) by the Autonomous University of Barcelona. He became an independent apheresis consultant in 2019 and consulted for several cell & gene therapy companies including CRISPR Therapeutics, BioNTech, BlueBird Bio, PACT Pharma, Editas and Aruvant. He started working for Bristol Myers Squibb in 2020 as the Associate Technical Director of Apheresis for Global MS&T.
.png)
Itai Benhar—Full Professor at the Shmunis School of Biomedicine and Cancer Research and Director of the Tel Aviv University for Combatting Pandemics. Prof. Benhar received in 1992 a PhD in Molecular Biology from the Hebrew University, Israel. Between 1992-1995, he was a post-doctoral fellow at the National Cancer Institute, NIH, working with Dr. Ira Pastan on recombinant immunotoxins. This was Prof. Benhar’s introduction to the fields of cancer research and targeted immunotherapy, in which he has been active ever since.
Prof. Benhar is an expert in the fields of antibody engineering, drug discovery and drug delivery with over 27 years of being active in these fields. His research is currently focused on: 1) evaluation of novel formats of bispecific antibodies as potential therapeutic agents. 2) Antibody discovery for treating cancer, allergy, inflammation and viral infections. 3) Targeted nanomedicines.
Prof. Benhar published >110 articles, 12 book chapters, and 19 patents.
Rohan Kamat obtained his PhD in Molecular Virology from The Tata Memorial Centre’s Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India, where he developed viral vectors for gene therapy. After a brief post doctoral fellowship in Neurobiology at NCBS, Bangalore, Rohan ventured into entrepreneurship where he founded Viravecs Labs and Straximm Therapeutics.
Currently Rohan heads the R&D division at Immuneel Therapeutics in Bangalore, India. Immuneel works on making cellular immune-therapies affordable to India and the sub-population. Immuneel’s first asset in clinical trails is a CD19 targeting CAR-T cell therapy for leukaemias and lymphomas.
Over 17 years of scientific research, business and management consulting experience. She worked on intein technologies at Princeton University. She is known for her leadership roles resulting in international business expansion, product innovation & launch, international operations redesigning with significant cost reduction and increase of productivity
